Dual roles of sulforaphane in cancer treatment

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 9, 2012, Pages 1132-1142

  Xu, Tongzhen ^a   Ren, Dongmei ^b   Sun, Xuefei ^a   Yang, Guotao ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Anti Cancer; Chemopreventive agent; Chemoresistance; Combination therapy; Isothiocyanates; Signaling pathway; Sulforaphane; Systemic toxicity

Indexed keywords

3 INDOLEMETHANOL; CISPLATIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HISTONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; SELENIUM; SULFORAPHANE; TRANSCRIPTION FACTOR NRF1; TRANSCRIPTION FACTOR NRF2;

ANGIOGENESIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER INVASION; CELL CYCLE; CELL DEATH; CELL VIABILITY; DOWN REGULATION; DRUG EFFICACY; GENE OVEREXPRESSION; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; METASTASIS; NEOPLASM; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; HUMANS; NEOPLASMS; NF-E2-RELATED FACTOR 2; SIGNAL TRANSDUCTION; THIOCYANATES;

EID: 84872249486     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012803529691     Document Type: Article

References (162)

1. Abratt, R.P.; Bezwoda, W.R.; Falkson, G.; Goedhals, L.; Hacking, D.; Rugg, T.A. Efficacy and safety profile of gemcitabine in nonsmall-cell lung cancer: a phase II study. J. Clin. Oncol., 1994, 12, 1535-1540.
2. Zhang, Y.; Talalay, P.; Cho, CG.; Posner, G.H. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl. Acad. Sci., U.S.A.,1992, 89, 2399-2403.
3. Fahey, J.W.; Talalay, P. Antioxidant functions of sulforaphane: a potent inducer of phase II detoxication enzymes. Food. Chem. Toxicol., 1999, 37, 973-979.
4. Zhang, Y.; Tang, L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. Acta. Pharmacol. Sin., 2007, 28, 1343-1354.
5. Myzak, MC.; Dashwood, R.H. Chemoprotection by sulforaphane: Keep one eye beyond Keap1. Cancer. Lett., 2006, 233, 208-218.
6. Jakubikova, J.; Bao, Y.P.; Sedlak, J. Isothiocyanates induce cell cycle arrest, apoptosis and mitochondrial potential depolarization in HL-60 and multidrug-resistant cell lines. Anticancer Research., 2005, 25, 3375-3386.
7. Juge N.; Mithen, R.F.; Traka, M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol. Life Sci., 2007, 64, 1105-1127.
8. Tang, L.; Zhang, Y.S. Mitochondria are the primary target in isothiocyanate-induced apoptosis in human bladder cancer cells. Mol. Cancer Ther., 2005, 4, 1250-1259.
9. Yeh, C.T.; Yen, G.C. Chemopreventive functions of sulforaphane: A potent inducer of antioxidant enzymes and apoptosis. J. Funct. Food., 2009, 1, 23-32.
10. McWalter, G.K.; Higgins, L.G.; McLellan, L.I.; Henderson, C.J.; Song, L.J.; Thornalley, P.J.; Itoh, K.; Yamamoto, M.; Hayes, J.D. Transcription factor nrf2 is essential for induction of NAD(P)H: quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. J. Nutr., 2004, 134, 3499s-3506s.
11. Keum, Y.S.; Owuor, E.D.; Kim, B.R.; Hu, R.; Kong, A.N.T. Involvement of Nrf2 and JNK1 in the activation of antioxidant responsive element (ARE) by chemopreventive agent phenethyl isothiocyanate (PEITC). Pharmaceut. Res., 2003, 20, 1351-1356.
12. Wang, X.J.; Sun, Z.; Villeneuve, N.F.; Zhang, S.; Zhao, F.; Li, Y.J.; Chen, W.M.; Yi, XF.; Zheng, W.X.; Wondrak, G.T. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis., 2008, 29, 1235-1243.
13. Lau, A.; Villeneuve, N.F.; Sun, Z.; Wong, P.K.; Zhang, D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res., 2008, 58, 262-270.
14. Chung, F.L.; Conaway, C.C.; Rao, C.V.; Reddy, B.S. Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis. 2000, 21, 2287-2291.
15. Clarke, J.D.; Dashwood, R.H.; Ho, E. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett., 2008, 269, 291-304.
16. Ambrosone, C.B.; McCann, S.E.; Freudenheim, J.L.; Marshall, J.R.; Zhang, Y.S.; Shields, P.G. Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J. Nutr., 2004, 134, 1134-1138.
17. van, Poppel. G.; Verhoeven, D.T.H.; Verhagen, H.; Goldbohm, R.A. Brassica vegetables and cancer prevention-Epidemiology and mechanisms. Adv. Nutr. Cancer, 1999, 472, 159-168.
18. Joseph, M.A.; Moysich, K.B.; Freudenheim, J.L.; Shields, P.G.; Bowman, ED.; Zhang, Y.S.; Marshall, J.R. Ambrosone CB, Cruciferous vegetables, genetic polymorphisms in glutathione Stransferases M1 and T1, and prostate cancer risk. Nutr. Cancer., 2004, 50, 206-213.
19. Mithen, R. Glucosinolates-biochemistry, genetics and biological activity. Plant Growth Regul., 2001, 34, 91-103.
20. Bennett, R.N.; Mellon, F.A.; Botting, N.P.; Eagles, J.; Rosa, E.A.S.; Williamson, G. Identification of the major glucosinolate (4-mercaptobutyl glucosinolate) in leaves of Eruca sativa L. (salad rocket). Phytochemistry., 2002, 61, 25-30.
21. Kushad, M.M.; Brown, A.F.; Kurilich, A.C.; Juvik, J.A.; Klein, BP.; Wallig, M.A.; Jeffery, E.H. Variation of glucosinolates in vegetable crops of Brassica oleracea. J. Agr. Food Chem., 1999, 47, 1541-1548.
22. Fimognari, C.; Nusse, M.; Cesari, R.; Iori, R.; Cantelli-Forti, G.; Hrelia, P. Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis., 2002, 23, 581-586.
23. Maheo, K.; Morel, F.; Langouet, S.; Kramer, H.; LeFerrec, E.; Ketterer, B.; Guillouzo, A. Inhibition of cytochromes P-450 and induction of glutathione S-transferases by sulforaphane in primary human and rat hepatocytes. Cancer. Res., 1997, 57, 3649-3652.
24. Matusheski, N.V.; Jeffery, E.H. Comparison of the bioactivity of two glucoraphanin hydrolysis products found in broccoli, sulforaphane and sulforaphane nitrile. J. Agr. Food Chem., 2001, 49, 5743-5749.
25. Pappa, G.; Strathmann, J.; Lowinger, M.; Bartsch, H.; Gerhauser, C. Quantitative combination effects between sulforaphane and 3, 3'-diindolylmethane on proliferation of human colon cancer cells in vitro. Carcinogenesis., 2007, 28, 1471-1477.
26. Zhang, Y.S. Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action. Mutat. Res-Fund. Mol., 2004, 555, 173-190.
27. Campas-Baypoli, O.N.; Sanchez-Machado, D.I.; Bueno-Solano, C.; Ramirez-Wong, B.; Lopez-Cervantes, J. HPLC method validation for measurement of sulforaphane level in broccoli by-products. Biomed. Chromatogr., 2010, 24, 387-392.
28. Zhang, Y.; Talalay, P. Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. Cancer. Res., 1994, 54, 1976s-1981s.
29. Lampe, J.W.; Peterson, S. Brassica, biotransformation and cancer risk: Genetic polymorphisms alter the preventive effects of cruciferous vegetables. J. Nutr., 2002, 132, 2991-2994.
30. Zhang, Y.; Kensler, T.W.; Cho, C.G.; Posner, G.H.; Talalay, P. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 3147-3150.
31. Chung, F.L.; Conaway, C.C.; Rao, C.V.; Reddy, B.S. Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis, 2000, 21, 2287-2291.
32. Hu. R.; Khor, T.O.; Shen, G.X.; Jeong, W.S.; Hebbar, V.; Chen, C.; Xu, C.J.; Reddy, B.; Chada, K.; Kong, A.N.T. Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. Carcinogenesis, 2006, 27, 2038-2046.
33. Myzak, M.C.; Dashwood, W.M.; Orner, G.A.; Ho, E.; Dashwood, R.H. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. Faseb. J., 2006, 20, 506-508.
34. Pham, N.A.; Jacobberger, J.W.; Schimmer, A.D.; Cao, P.; Gronda, M.; Hedley, D.W. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Mol. Cancer. Ther., 2004, 3, 1239-1248.
35. Singh, A.V.; Xiao, D.; Lew, K.L.; Dhir, R.; Singh, S.V. Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis, 2004, 25, 83-90.
36. Fahey, J.W.; Talalay, P. Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food. Chem. Toxicol., 1999, 37, 973-979.
37. Zhang, Y.; Tang, L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. Acta. Pharmacol. Sin., 2007, 28, 1343-1354.
38. Brooks, J.D.; Paton, V.G.; Vidanes, G. Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer. Epidemiol. Biomarkers. Prev., 2001, 10, 949-954.
39. Sharma, C.; Sadrieh, L.; Priyani, A.; Ahmed, M.; Hassan, A.H.; Hussain, A. Anti-carcinogenic effects of sulforaphane in association with its apoptosis-inducing and anti-inflammatory properties in human cervical cancer cells. Cancer. Epidemiol., 2010, 35(3), 272-278.
40. Matsui, T.A.; Murata, H.; Sakabe, T.; Sowa, Y.; Horie, N.; Nakanishi, R.; Sakai, T.; Kubo, T. Sulforaphane induces cell cycle arrest and apoptosis in murine osteosarcoma cells in vitro and inhibits tumor growth in vivo. Oncol. Rep., 2007, 18, 1263-1268.
41. Fahey, J.W.; Haristoy, X.; Dolan, P.M.; Kensler, T.W.; Scholtus, I.; Stephenson, K.K.; Talalay, P.; Lozniewski, A. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. P. Natl. Acad. Sci. USA., 2002, 99, 7610-7615.
42. Qazi, A.; Pal, J.; Maitah, M.; Fulciniti, M.; Pelluru, D.; Nanjappa, P.; Lee, S.; Batchu, R.B.; Prasad, M.; Bryant, C.S. Anticancer activity of a broccoli derivative, sulforaphane, in barrett adenocarcinoma: potential use in chemoprevention and as adjuvant in chemotherapy. Transl. Oncol., 2010, 3, 389-399.
43. Dinkova-Kostova, A.T.; Jenkins, S.N.; Fahey, J.W.; Ye, L.X.; Wehage, S.L.; Liby, K.T.; Stephenson, K.K.; Wade, K.L.; Talalay, P. Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. Cancer. Lett., 2006, 240, 243-252.
44. Xu, C.J.; Huang, M.T.; Shen, G.X.; Yuan, X.L.; Lin, W.; Khor, T.O.; Conney, A.H.; Kong, A.N.T. Inhibition of 7, 12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer. Res., 2006, 66, 8293-8296.
45. Fimognari, C.; Lenzi, M.; Hrelia, P. Interaction of the isothiocyanate sulforaphane with drug disposition and metabolism: Pharmacological and toxicological implications. Curr. Drug. Metab., 2008, 9, 668-678.
46. Barcelo, S.; Gardiner, J.M.; Gescher, A.; Chipman, J.K. CYP2E1-mediated mechanism of anti-genotoxicity of the broccoli constituent sulforaphane. Carcinogenesis, 1996, 17, 277-282.
47. Dashwood, R.H. Modulation of heterocyclic amine-induced mutagenicity and carcinogenicity: an 'A-to-Z' guide to chemopreventive agents, promoters, and transgenic models. Mutat. Res-Rev. Mutat., 2002, 511, 89-112.
48. Bacon, J.R.; Williamson, G.; Garner, R.C.; Lappin, G.; Langouet, S.; Bao, Y. Sulforaphane and quercetin modulate PhIP-DNA adduct formation in human HepG2 cells and hepatocytes. Carcinogenesis, 2003, 24, 1903-1911.
49. Gerhauser, C.; You, M.; Liu, J.; Moriarty, R.M.; Hawthorne, M.; Mehta, R.G.; Moon, R.C.; Pezzuto, J.M. Cancer chemopreventive potential of sulforamate, a novel analogue of sulforaphane that induces phase 2 drug-metabolizing enzymes. Cancer. Res., 1997, 57, 272-278.
50. Basten, G.P.; Bao, Y.; Williamson, G. Sulforaphane and its glutathione conjugate but not sulforaphane nitrile induce UDP-glucuronosyl transferase (UGT1A1) and glutathione transferase (GSTA1) in cultured cells. Carcinogenesis, 2002, 23, 1399-1404.
51. Hintze, K.J.; Keck, A.S.; Finley, J.W.; Jeffery, E.H. Induction of hepatic thioredoxin reductase activity by sulforaphane, both in Hepa1c1c7 cells and in male Fisher 344 rats. J. Nutr. Biochem., 2003, 14, 173-179.
52. Jowsey, I.R.; Jiang, Q.; Itoh, K.; Yamamoto, M.; Hayes, J.D. Expression of the aflatoxin B1-8, 9-epoxide-metabolizing murine glutathione S-transferase A3 subunit is regulated by the Nrf2 transcription factor through an antioxidant response element. Mol. Pharmacol., 2003, 64, 1018-1028.
53. Munday, R.; Munday, C.M. Induction of phase II detoxification enzymes in rats by plant-derived isothiocyanates: comparison of allyl isothiocyanate with sulforaphane and related compounds. J. Agric. Food. Chem., 2004, 52, 1867-1871.
54. Svehlikova, V.; Wang, S.R.; Jakubikova, J.; Williamson, G.; Mithen, R.; Bao, Y.P. Interactions between sulforaphane and apigenin in the induction of UGT1A1 and GSTA1 in CaCo-2 cells. Carcinogenesis, 2004, 25, 1629-1637.
55. Hu, R.; Hebbar, V.; Kim, B.R.; Chen, C.; Winnik, B.; Buckley, B.; Soteropoulos, P.; Tolias, P.; Hart, R.P.; Kong, A.N.T. In vivo pharmacokinetics and regulation of gene expression profiles by isothiocyanate sulforaphane in the rat. J. Pharmacol. Exp. Ther., 2004, 310, 263-271.
56. Bertl, E.; Bartsch, H.; Gerhauser, C. Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Mol. Cancer. Ther., 2006, 5, 575-585.
57. Baek, S.H.; Park, M.; Suh, J.H.; Choi, H.S. Protective effects of an extract of young radish (Raphanus sativus L) cultivated with sulfur (sulfur-radish extract) and of sulforaphane on carbon tetrachloride-induced hepatotoxicity. Biosci. Biotech. Bioch., 2008, 72, 1176-1182.
58. Hong, F.; Sekhar, K.R.; Freeman, M.L.; Liebler, D.C. Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. J. Biol. Chem., 2005, 280, 31768-31775.
59. Luo, Y.; Eggler, AL.; Liu, D.T.; Liu, G.W.; Mesecar, AD.; van Breemen, R.B. Sites of alkylation of human Keap1 by natural Chemoprevention agents. J. Am. Soc. Mass. Spectr., 2007, 18, 2226-2232.
60. Eggler, A.L.; Luo, Y.; van Breemen, R.B.; Mesecar, A.D. Identification of the highly reactive cysteine 151 in the chemopreventive agent-sensor Keap1 protein is method-dependent. Chem. Res. Toxicol., 2007, 20, 1878-1884.
61. Eggler, A.L.; Liu, G.W.; Pezzuto, J.M.; van Breemen, R.B.; Mesecar, A.D. Modifying specific cysteines of the electrophilesensing human Keap1 disrupt binding to the protein is insufficient to Nrf2 domain Neh2. P. Natl. Acad. Sci. USA., 2005, 102, 10070-10075.
62. Zhang, D.D.; Hannink, M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell. Biol., 2003, 23, 8137-8151.
63. Dinkova-Kostova, A.T.; Holtzclaw, W.D.; Cole, R.N.; Itoh, K.; Wakabayashi, N.; Katoh, Y.; Yamamoto, M.; Talalay, P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. P. Natl. Acad. Sci. USA., 2002, 99, 11908-11913.
64. Levonen, A.L.; Landar, A.; Ramachandran, A.; Ceaser, E.K.; Dickinson, D.A.; Zanoni, G.; Morrow, J.D.; Darley-Usmar, V.M. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem. J., 2004, 378, 373-382.
65. Wakabayashi, N.; Dinkova-Kostova, A.T.; Holtzclaw, WD.; Kang, M.I.; Kobayashi, A.; Yamamoto, M.; Kensle, r TW.; Talalay, P. Protection against electrophile and oxidant stress by induction of the phase 2 response: Fate of cysteines of the Keap1 sensor modified by inducers. P. Natl. Acad. Sci., USA. 2004, 101, 2040-2045.
66. Stewart, D.; Killeen, E.; Naquin, R.; Alam, S.; Alam, J. Degradation of transcription factor Nrf2 via the ubiquitinproteasome pathway and stabilization by cadmium. J. Biol. Chem., 2003, 278, 2396-2402.
67. McMahon, M.; Itoh, K.; Yamamoto, M.; Hayes, J.D. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J. Biol. Chem., 2003, 278, 21592-21600.
68. Kobayashi, A.; Kang, M.I.; Okawa, H.; Ohtsuji, M.; Zenke, Y.; Chiba, T.; Igarashi, K.; Yamamoto, M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate for proteasomal degradation of Nrf2. Mol. Cell. Biol., 2004, 24, 7130-7139.
69. Sun, Z.; Zhang, S.; Chan, J.Y.; Zhang, D.D. Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2. Mol. Cell. Biol., 2007, 27, 6334-6349.
70. Florczyk, U.; Loboda, A.; Stachurska, A.; Jozkowicz, A.; Dulak, J. [Role of Nrf2 transcription factor in cellular response to oxidative stress]. Postepy. Biochem., 2010, 56, 147-155.
71. Yu, R.; Lei, W.; Mandlekar, S.; Weber, M.J.; Der, C.J.; Wu, J.; Kong, A.N.T. Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J. Biol. Chem., 1999, 274, 27545-27552.
72. Yu, R.; Chen, C.; Mo, Y.Y.; Hebbar, V.; Owuor, E.D.; Tan, TH.; Kong, A.N. Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. J. Biol. Chem., 2000, 275, 39907-39913.
73. Thornalley, P.J. Isothiocyanates: mechanism of cancer chemopreventive action. Anti-Cancer. Drug., 2002, 13, 331-338.
74. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. Nature., 2000, 407, 249-257.
75. Sharma, R.A.; Harris, A.L.; Dalgleish, A.G.; Steward, W.P.; O'Bryne K.J. Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet. Oncology., 2001, 2, 726-732.
76. Tosetti, F.; Ferrari, N.; DeFlora, S.; Albini, A. 'Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. Faseb. J., 2002, 16, 2-14.
77. Bhat, T.A.; Moon, J.S.; Lee, S.; Yim, D.; Singh, R.P. Inhibition of angiogenic attributes by decursin in endothelial cells and ex vivo rat aortic ring angiogenesis model. Indian. J. Exp. Biol., 2011, 49, 848-856.
78. Egeblad, M.; Werb, Z. New functions for the matrix metallo proteinases in cancer progression. Nat. Rev. Cancer., 2002, 2, 161-174.
79. Rundhaug, J.E. Matrix metalloproteinases, reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clinical. Cancer. Research., 2003, 9, 551-554.
80. Josko, J.; Mazurek, M. Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med, Sci. Monitor., 2004, 10, Ra89-Ra98.
81. Xie, K.P.; Wei, D.Y.; Shi, Q.; Huang, S.Y. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine. Growth. F. R. 2004, 15, 297-324.
82. Myzak, M.C.; Karplus, P.A.; Chung, F.L.; Dashwood, R.H. A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase. Cancer. Res., 2004, 64, 5767-5774.
83. Marks, P.A.; Richon, V.M.; Rifkind, R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer. Inst., 2000, 92, 1210-1216.
84. Rosato, R.R.; Grant, S. Histone deacetylase inhibitors in cancer therapy. Cancer. Biol. Ther., 2003, 2, 30-37.
85. Woo, S.H.; Frechette, S.; Abou, Khalil. E.; Bouchain, G.; Vaisburg, A.; Bernstein, N.; Moradei, O.; Leit, S.; Allan, M.; Fournel, M. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. J. Med. Chem., 2002, 45, 2877-2885.
86. Weidle, U.H.; Grossmann, A. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer. Res., 2000, 20, 1471-1485.
87. Remiszewski, S.W.; Sambucetti, L.C.; Atadja, P.; Bair, K.W.; Cornell, W.D.; Green, M.A.; Howell, K.L.; Jung, M.; Kwon, P.; Trogani, N. Inhibitors of human histone deacetylase: Synthesis and enzyme and cellular activity of straight chain hydroxamates. J. Med. Chem., 2002, 45, 753-757.
88. Wang, L.G.; Liu, X.M.; Fang, Y.; Dai, W.; Chiao, F.B.; Puccio, G.M.; Feng, J.; Liu, D.; Chiao, J.W. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int. J. Oncol., 2008, 33, 375-380.
89. Myzak, M.C.; Karplus, P.A.; Chung, F.L.; Dashwood, R.H. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer. Res., 2004, 64, 5767-5774.
90. Myzak, M.C.; Karplus, P.A.; Chung, F.L.; Dashwood, R.H. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer. Res., 2004, 64, 5767-5774.
91. Johnstone, R.W.; Ruefli, A.A.; Lowe, S.W. Apoptosis: A link between cancer genetics and chemotherapy. Cell., 2002, 108, 153-164.
92. Sun, S.Y.; Hail, N.; Lotan, R. Apoptosis as a novel target for cancer chemoprevention. J. Natl. Cancer. I., 2004, 96, 662-672.
93. Tomczyk, J.; Olejnik, A. Sulforaphane--a possible agent in prevention and therapy of cancer. Postepy. Hig. Med. Dosw. (Online), 2010, 64, 590-603.
94. Fimognari, C.; Lenzi, M.; Sciuscio, D.; Cantelli-Forti, G.; Hrelia, P. Cell-cycle specificity of sulforaphane-mediated apoptosis in Jurkat T-leukemia cells. In Vivo., 2007, 21, 377-380.
95. Cheung, K.L.; Kong, A.N. Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS. J., 2010, 12, 87-97.
96. Park, S.Y.; Kim, G.Y.; Bae, S.J.; Yoo, Y.H.; Choi, Y.H. Induction of apoptosis by isothiocyanate sulforaphane in human cervical carcinoma HeLa and hepatocarcinoma HepG2 cells through activation of caspase-3. Oncol. Rep., 2007, 18, 181-187.
97. Holmes, K.; Egan, B.; Swan, N.; O'Morain, C. Genetic mechanisms and aberrant gene expression during the development of gastric intestinal metaplasia and adenocarcinoma. Curr. Genomics., 2007, 8, 379-397.
98. Blagosklonny, M.V. Carcinogenesis, cancer therapy and chemoprevention. Cell. Death. Differ., 2005, 12, 592-602.
99. Krishnan, K.; Campbell, S.; Abdel-Rahman, F.; Whaley, S.;Stone, W.L. Cancer chemoprevention drug targets. Curr. Drug Targets., 2003, 4, 45-54.
100. Smith, J.J.; Tully, P.; Padberg, R.M. Chemoprevention: a primary cancer prevention strategy. Semin. Oncol. Nurs., 2005, 21, 243-251.
101. Singletary, K.; MacDonald, C. Inhibiton of benzo[a]pyrene-(BP) and 1, 6-dinitropyrene (DNP)-DNA adduct formation in human mammary epithelial cells by dibenzoylmethane and sulforaphane. Faseb. J., 2000, 14, A170-A170.
102. Fahey, J.W.; Haristoy, X.; Dolan, P.M.; Kensler, T.W.; Scholtus, I.; Stephenson, K.K.; Talalay, P.; Lozniewski, A. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 7610-7615.
103. Fimognari, C.; Nusse, M.; Berti, F.; Iori, R.; Cantelli-Forti, G.; Hrelia, P. Cyclin D3 and p53 mediate sulforaphane-induced cell cycle delay and apoptosis in non-transformed human T lymphocytes. Cell. Mol. Life. Sci., 2002, 59, 2004-2012.
104. Pham, N.A.; Jacobberger, J.W.; Schimmer, A.D.; Cao, P.J.; Gronda, M.; Hedley, D.W. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Mol. Cancer. Ther., 2004, 3, 1239-1248.
105. Bryant, C.S.; Kumar, S.; Chamala, S.; Shah, J.; Pal, J.; Haider, M.; Seward, S.; Qazi, A.M.; Morris, R.; Semaan, A. Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells. Mol. Cancer., 2010, 9, 243-251.
106. Park, S.Y.; Kim, G.Y.; Bae, S.J.; Yoo, YH.; Choi, Y.H. Induction of apoptosis by isothiocyanate sulforaphane in human cervical carcinoma HeLa and hepatocarcinoma HepG2 cells through activation of caspase-3. Oncology Reports., 2007, 18, 181-187.
107. Juge, N.; Mithen, R.F.; Traka, M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell. Mol. Life. Sci., 2007, 64, 1105-1127.
108. Tang, L.; Zhang, Y. Mitochondria are the primary target in isothiocyanate-induced apoptosis in human bladder cancer cells. Mol. Cancer. Ther., 2005, 4, 1250-1259.
109. Karmakar, S.; Weinberg, M.S.; Banik, N.L.; Patel, S.J.; Ray, S.K. Activation of multiple molecular mechanisms for apoptosis in human malignant glioblastoma T98G and U87MG cells treated with sulforaphane. Neuroscience., 2006, 141, 1265-1280.
110. Papi, A.; Orlandi, M.; Bartolini, G.; Barillari, J.; Iori, R.; Paolini, M.; Ferroni, F.; Fumo, M.G.; Pedulli, G.F.; Valgimigli, L. Cytotoxic and antioxidant activity of 4-methylthio-3-butenyl isothiocyanate from Raphanus sativus L. (Kaiware daikon) sprouts. J. Agr. Food. Chem., 2008, 56, 875-883.
111. Yeh, C.T.; Yen, G.C. Effect of sulforaphane on metallothionein expression and induction of apoptosis in human hepatoma HepG2 cells. Carcinogenesis, 2005, 26, 2138-2148.
112. Pappa, G.; Lichtenberg, M.; Iori, R.; Barillari, J.; Bartsch, H.; Gerhauser, C. Comparison of growth inhibition profiles and mechanisms of apoptosis induction in human colon cancer cell lines by isothiocyanates and indoles from Brassicaceae. Mutat. Res-Fund. Mol. M., 2006, 599, 76-87.
113. Matsui, T.A.; Murata, H.; Sakabe, T.; Sowa, Y.; Horie, N.; Nakanishi, R.; Sakai, T.; Kubo, T. Sulforaphane induces cell cycle arrest and apoptosis in murine osteosarcoma cells in vitro and inhibits tumor growth in vivo. Oncology Reports., 2007, 18, 1263-1268.
114. Chuang, L.T.; Moqattash, S.T.; Gretz, H.F.; Nezhat, F.; Rahaman, J.; Chiao, J.W. Sulforaphane induces growth arrest and apoptosis in human ovarian cancer cells. Acta. Obstet. Gyn. Scan., 2007, 86, 1263-1268.
115. Mi, L.X.; Xiao, Z.; Hood, B.L.; Dakshanamurthy, S.; Wang, X.T.; Govind, S.; Conrads, T.P.; Veenstra, T.D.; Chung, F.L. Covalent binding to tubulin by isothiocyanates-A mechanism of cell growth arrest and apoptosis. J. Biol. Chem., 2008, 283, 22136-22146.
116. Myzak, M.C.; Hardin, K.; Wang, R.; Dashwood, R.H.; Ho, E. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis, 2006, 27, 811-819.
117. Sarkar, F.H.; Li, Y.W. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer. Res., 2006, 66, 3347-3350.
118. Tannock, I.F.; Osoba, D.; Stockler, M.R.; Ernst, D.S.; Neville, A.J.; Moore, M.J.; Armitage, G.R.; Wilson, J.J.; Venner, P.M.; Coppin, C.M. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol., 1996, 14, 1756-1764.
119. Lev-Ari, S.; Vexler, A.; Starr, A.; Ashkenazy-Voghera, M.; Greif, J.; Aderka, D.; Ben-Yosef, R. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest., 2007, 25, 411-418.
120. Davis, J.M.; Navolanic, P.M.; Weinstein-Oppenheimer, C.R.; Steelman, L.S.; Hu, W.; Konopleva, M.; Blagosklonny, M.V.; McCubrey, J.A. Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin. Cancer Res., 2003, 9, 1161-1170.
121. Sharma, C.; Ahmed, T.; Sasidharan, S.; Ahmed, M.; Hussain, A. Use of gemcitabine and ginger extract infusion may improve the efficiency of cervical cancer treatment. Afr. J. Biotechnol., 2009, 8, 7087-7093.
122. Veltkamp, S.A.; Pluim, D.; van Eijndhoven, M.A.J.; Bolijn, M.J.; Ong, F.H.G. Govindarajan, R.; Unadkat, J.D.; Beijnen, J.H.; Schellens, J.H.M. New insights into the pharmacology and cytotoxicity of gemcitabine and 2 ', 2 '-difluorodeoxyuridine. Mol. Cancer. Ther., 2008, 7, 2415-2425.
123. Li. Y.; Ahmed, F.; Ali, S.; Philip, P.A.; Kucuk, O.; Sarkar, F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer. Res., 2005, 65, 6934-6942.
124. Banerjee, S.; Zhang, Y.X.; Ali, S.; Bhuiyan, M.; Wang, Z.W.; Chiao, P.J.; Philip, P.A.; Abbruzzese, J.; Sarkar, F.H. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer. Res., 2005, 65, 9064-9072.
125. Li, Y.W.; Ellis, K.L.; Ali, S.; El-Rayes, B.F.; Nedeljkovic-Kurepa, A.; Kucuk, O.; Philip, P.A.; Sarkar, F.H. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappa B in BxPC-3 pancreatic cancer cell line. Pancreas., 2004, 28, E90-E95.
126. Zhang, B.; Shi, Z.L.; Liu, B.; Yan, X.B.; Feng, J.; Tao, H.M. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappa B. Anti-Cancer. Drug., 2010, 21, 288-296.
127. Chan, M.M.; Fong, D.; Soprano, K.J.; Holmes, W.F.; Heverling, H. Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J. Cell. Physiol., 2003, 194, 63-70.
128. Lebwohl, D.; Canetta, R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur. J. Cancer., 1998, 34, 1522-1534.
129. Pabla, N.; Dong, Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney. Int., 2008, 73, 994-1007.
130. Tsang, R.Y.; Al-Fayea, T.; Au, H.J. Cisplatin overdose: toxicities and management. Drug. Saf., 2009, 32, 1109-1122.
131. Angeloni, C.; Leoncini, E.; Malaguti, M.; Angelini, S.; Hrelia, P.; Hrelia, S. Modulation of Phase II Enzymes by Sulforaphane: Implications for Its Cardioprotective Potential. J. Agr. Food. Chem., 2009, 57, 5615-5622.
132. Yoon, H.Y.; Kang, N.I.; Lee, H.K.; Jang, K.Y.; Park, J.W.; Park, B.H. Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem. Pharmacol., 2008, 75, 2214-2223.
133. Innamorato, N.G.; Rojo, A.I.; Garcia-Yague, A.J.; Yamamoto, M.; de Ceballos, M.L.; Cuadrado, A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J. Immunol., 2008, 181, 680-689.
134. Guerrero-Beltran, C.E.; Calderon-Oliver, M.; Martinez-Abundis, E.; Tapia, E.; Zarco-Marquez, G.; Zazueta, C.; Pedraza-Chaverri, J. Protective effect of sulforaphane against cisplatin-induced mitochondrial alterations and impairment in the activity of NAD(P)H: Quinone oxidoreductase 1 and gamma glutamyl cysteine ligase: Studies in mitochondria isolated from rat kidney and in LLC-PK1 cells. Toxicol. Lett., 2010, 199, 80-92.
135. Keck, A.S.; Finley, J.W. Cruciferous vegetables: cancer protective mechanisms of glucosinolate hydrolysis products and selenium. Integr. Cancer. Ther., 2004, 3, 5-12.
136. Brigelius-Flohe, R.; Banning, A. Part of the series: from dietary antioxidants to regulators in cellular signaling and gene regulation. Sulforaphane and selenium, partners in adaptive response and prevention of cancer. Free. Radic. Res., 2006, 40, 775-787.
137. Aoki, Y.; Sato, H.; Nishimura, N.; Takahashi, S.; Itoh, K.; Yamamoto, M. Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol. Appl. Pharm., 2001, 173, 154-160.
138. Braun, S.; Hanselmann, C.; Gassmann, M.G.; Keller, U.A.D.; Born-Berclaz, C.; Chan, K.M.; Kan, Y.W.; Werner, S. Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol. Cell. Biol., 2002, 22, 5492-5505.
139. Cho, H.Y.; Reddy, S.P.M.; Yamamoto, M.; Kleeberge, r S.R. The transcription factor NRF2 protects against pulmonary fibrosis. Faseb. J., 2004, 18, 1258-+.
140. Suh, J.H.; Shenvi, S.V.; Dixon, B.M.; Liu, H.L.; Jaiswal, A.K.; Liu, R.M.; Hagen, T.M. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. P. Natl. Acad. Sci. U.S.A., 2004, 101, 3381-3386.
141. Ishii, Y.; Itoh, K.; Morishima, Y.; Kimura, T.; Kiwamoto, T.; Iizuka, T.; Hegab, A.E.; Hosoya, T.; Nomura, A.; Sakamoto, T. Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J. Immunol., 2005, 175, 6968-6975.
142. Shih, A.Y.; Imbeault, S.; Barakauskas, V.; Erb, H.; Jiang, L.; Li, P.; Murphy, T.H. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J. Biol. Chem., 2005, 280, 22925-22936.
143. Yates, M.S.; Kensler, T.W. Chemopreventive promise of targeting the Nrf2 pathway. Drug. News. Perspect., 2007, 20, 109-117.
144. Kensler, T.W.; Chen, J.G.; Egner, PA.; Fahey, J.W.; Jacobson, L.P.; Stephenson, K.K.; Ye, L.; Coady, J.L.; Wang, J.B.; Wu, Y. Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 2605-2613.
145. Singh, A.; Misra, V.; Thimmulappa, R.K.; Lee, H.; Ames, S.; Hoque, MO.; Herman, J.G.; Baylin, S.B.; Sidransky, D.; Gabrielson, E. Dysfunctional KEAP1-NRF2 interaction in nonsmall-cell lung cancer. PLoS. Med., 2006, 3, e420.
146. Padmanabhan, B.; Tong, K.I.; Ohta, T.; Nakamura, Y.; Scharlock, M.; Ohtsuji, M.; Kang, M.I.; Kobayashi, A.; Yokoyama, S.; Yamamoto, M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol. Cell., 2006, 21, 689-700.
147. Stacy, D.R.; Ely, K.; Massion, P.P.; Yarbrough, W.G.; Hallahan, D.E.; Sekhar, K.R.; Freeman, M.L. Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck., 2006, 28, 813-818.
148. Wang, X.J.; Sun, Z.; Villeneuve, N.F.; Zhang, S.; Zhao, F.; Li, Y.; Chen, W.; Yi, X.; Zheng, W.; Wondrak, G.T. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis, 2008, 29, 1235-1243.
149. Cho, J.M.; Manandhar, S.; Lee, H.R.; Park, H.M.; Kwak, M.K. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett., 2008, 260, 96-108.
150. Bertilsson, G.; Heidrich, J.; Svensson, K.; Asman, M.; Jendeberg, L.; Sydow-Backman, M.; Ohlsson, R.; Postlind, H.; Blomquist, P.; Berkenstam, A. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. U S A., 1998, 95, 12208-12213.
151. Miki, Y.; Suzuki, T.; Kitada, K.; Yabuki, N.; Shibuya, R.; Moriya, T.; Ishida, T.; Ohuchi, N.; Blumberg, B.; Sasano, H. Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res., 2006, 66, 535-542.
152. Zhou, J.; Liu, M.; Zhai, Y.; Xie, W. The antiapoptotic role of pregnane X receptor in human colon cancer cells. Mol. Endocrinol., 2008, 22, 868-880.
153. Mensah-Osman, E.J.; Thomas, D.G.; Tabb, M.; Larios, J.M.; Hughes, D.P.; Giordano, T.J.; Lizyness, M.L.; Rae, J.M.; Blumberg, B.; Hollenberg, P.F. Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer., 2007, 109, 957-965.
154. Gupta, D.; Venkatesh, M.; Wang, H.; Kim, S.; Sinz, M.; Goldberg, GL.; Whitney, K.; Longley, C.; Mani, S. Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin. Cancer. Res., 2008, 14, 5332-5340.
155. Masuyama, H.; Hiramatsu, Y.; Kodama, J.; Kudo, T. Expression and potential roles of pregnane X receptor in endometrial cancer. J. Clin. Endocrinol. Metab., 2003, 88, 4446-4454.
156. Masuyama, H.; Nakatsukasa, H.; Takamoto, N.; Hiramatsu, Y. Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells. Mol. Pharmacol., 2007, 72, 1045-1053.
157. Chen, Y.; Nie, D. Pregnane X receptor and its potential role in drug resistance in cancer treatment. Recent Pat. Anticancer Drug Discov., 2009, 4, 19-27.
158. Zucchini, N.; de Sousa, G.; Bailly-Maitre, B.; Gugenheim, J.; Bars, R.; Lemaire, G.; Rahmani, R. Regulation of Bcl-2 and Bcl-xL antiapoptotic protein expression by nuclear receptor PXR in primary cultures of human and rat hepatocytes. Biochim. Biophys. Acta., 2005, 1745, 48-58.
159. Guzelian, J.; Barwick, J.L.; Hunter, L.; Phang, T.L.; Quattrochi, L.C.; Guzelian, P.S. Identification of genes controlled by the pregnane X receptor by microarray analysis of mRNAs from pregnenolone 16alpha-carbonitrile-treated rats. Toxicol. Sci., 2006, 94, 379-387.
160. Rosenfeld, J.M.; Vargas, R.; Jr.; Xie, W.; Evans, R.M. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol. Endocrinol., 2003, 17, 1268-1282.
161. Zhou, C.; Poulton, E.J.; Grun, F.; Bammler, T.K.; Blumberg, B.; Thummel, KE.; Eaton, D.L. The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol. Pharmacol., 2007, 71, 220-229.
162. Hu, R.; Hebbar, V.; Kim, B.R.; Chen, C.; Winnik, B.; Buckley, B.; Soteropoulos, P.; Tolias, P.; Hart, R.P.; Kong, A.N. In vivo pharmacokinetics and regulation of gene expression profiles by isothiocyanate sulforaphane in the rat. J. Pharmacol. Exp. Ther., 2004, 310, 263-271.